Immune checkpoint inhibitors have taken the oncology space by storm and there's a lot of excitement about their potential across a wide range of indications, including in difficult-to-treat cancers. As drug developers turn to combinatorial approaches to get an edge in this competitive environment, market access and cost will be key variables that will shape uptake of immunotherapy-based combinations.
He has expertise across a wide range of indications and topics, including prostate cancer, multiple myeloma and other hematological malignancies, and cancer immunotherapies.
Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders.
He holds a M.Sc. in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a B.Sc. in life sciences from the Pierre and Marie Curie-Paris VI University.